853results about How to "Good analgesic effect" patented technology

Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at a such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours. A method of titrating a human patient utilizing these sustained release opioid formulations is also disclosed.

Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at a such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours. A method of titrating a human patient utilizing these sustained release opioid formulations is also disclosed.

1-phenyl-3-dimethylaminopropane compounds corresponding to the formula I a method of preparing them, and the use of these substances as analgesic active ingredients in pharmaceutical compositions.

Disclosed is a pharmaceutical composition, comprising a combination of a dose of meloxicam or a pharmaceutically acceptable salt thereof and a dose of oxycodone or a pharmaceutically acceptable salt thereof, said combination in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising administering to the patient a combination of a dose of meloxicam or a pharmaceutically acceptable salt thereof and a dose of oxycodone or a pharmaceutically acceptable salt thereof such that the dosing interval of the meloxicam overlaps with the dosing interval of the oxycodone, said combination in an amount sufficient to provide an analgesic effect in a human patient.

The invention relates to a 2-(2-(2, 6-dichlorophenyl amido) phenyl) methyl acetate, relative synthesis method and application, belonging to the technical field of chemical pharmacy, which comprises that adds acid into diclofenac salt to acidify the salt into diclofenac, reacts diclofenac with methanol, or adds acid into diclofenac salt to acidify the salt into diclofenac, to be reacted with chloracetyl chloride to obtain 2-(2-(2, 6-dichlorophenyl amido) phenyl) methyl acetate. The inventive drug has significant anti-inflammatory and analgesic effects.

An object of the present invention is to provide a novel fused-ring compound which has a FAAH inhibitory effect and is useful as an analgesic.The present invention relates to a compound represented by formula (I):wherein symbols are as defined in the specification, or salt thereof.

To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound. The object has been attained by a condensed benzamide compound represented by the following formula (the symbols in the formula have the same meanings defined in the specification) or its salt:

Apparatus for providing transcutaneous electrical nerve stimulation (TENS) therapy to a user, the apparatus comprising: a housing; an application unit for providing mechanical coupling between the housing and the user's body; a stimulation unit for electrically stimulating at least one nerve of the user; a sensing unit for sensing the user's body movement and body orientation; and a reporting unit for providing the user with feedback based on the user's sensed body movement and body orientation.

The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and / or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and / or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.

Disclosed is a pharmaceutical composition, comprising two analgesic compounds and / or pharmaceutically acceptable salts thereof consisting of celecoxib and / or at least one pharmaceutically acceptable salt thereof and oxycodone and / or at least one pharmaceutically acceptable salt thereof, said two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising orally administering to the patient an oral dosage form comprising two analgesic compounds consisting of celecoxib and / or at least one pharmaceutically acceptable salt thereof and oxycodone and / or at least one pharmaceutically acceptable salt thereof, said two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient.

The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R3 is a hydrogen atom or a C1-6 alkyl group, R4 is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, and neuralgia.

Topical treatments for neuropathy are described. The treatments include topical formulations of NMDA antagonists and one additional active ingredient. In one example, the formulation includes ketamine and gabapentin for the treatment of a subject's neuropathy. These transdermal or topical compositions provide a surprising degree of effective relief from the symptoms of peripheral neuropathy and can be administered to subjects to treat various neuropathies.

The invention relates to a medicinal composition and a preparation method and application thereof. The medicinal composition is prepared from ibuprofen and arginine serving as medicinal active ingredients in a molar ratio of 1:1 and pharmaceutically acceptable auxiliary materials. The composition can be prepared into an oral preparation and an injection preparation for treating related symptoms such as fever, inflammation, pain and the like.

The invention discloses compound benzocaine externally-applied medicinal liquid, gel or ointment. The medicine liquid, gel or ointment, which contains a compound medicine, is filled into an applicator to be applied on oral wound surfaces, ulcer surfaces and mucosa surfaces, treat tooth diseases, narcotize and relieve itching caused by haemorrhoids, treat itch and lubricate a nasopharyngeal catheter, inner root sight glass and the like for relieving pain.

Provided are pharmaceutical compositions and methods for the alleviation of pain in a patient with optimal ratios of morphine and oxycodone that provide superior analgesic efficacy and lower incidence of adverse side effects compared to morphine and oxycodone alone. The pharmaceutical compositions comprise morphine and oxycodone, or pharmaceutically acceptable salts thereof, in ratios of about 3 to 2 to about 1 to 2, morphine to oxycodone by weight.

The invention relates to a quadruple long-acting medicine composition and application thereof to pain treatment, in particular to the quadruple long-acting medicine composition. The medicine composition contains lappaconitine, tetrahydropalmatine, fumaric acid and succinic acid of the treatment and / or effective quantity as active ingredients. Compared with a composition formed by single ingredients or two ingredients or three ingredients, the quadruple long-acting medicine composition has the characteristics of good water solubility, good curative effect, low toxic and side effects and the like. The quadruple long-acting medicine composition can be used for preventing and / or treating diseases relevant to the pain; the pain includes tumor pain, pain of cancer patients after chemotherapy, joint pain, trauma pain, postoperative pain, inflammatory pain, pain caused by drug detoxification or drug addicition and intractable pain due to unknown reasons. The quadruple long-acting medicine composition can also be used for sedation, hypnosis, collaborative anesthesia, antiarrhythmia and the like.

The invention synthesizes four novel endomorphin-1 analogs, and belongs to the technical field of biochemistry. The endomorphin-1 analogs are prepared by performing N-end guanidyl formation at the first-position Tyr of endomorphin-1, replacing the second-position Pro by D-Ala, replacing the third-position Trp by Gly, and replacing the fourth-position Phe by Trp or performing para-position chlorination and fluorination modification or no modification on a benzene ring of Phe. The synthesized endomorphin-1 analogs are subjected to a series of physiological and pharmacological activity identification such as radio-ligand receptor binding assays, isolated organ bioactivity identification experiments, isolated enzymolysis stability experiments, analgesic tests with water bath and medicine tolerance experiments, show high affinity activity, high enzymolysis stability and high analgesic activity, and hardly cause tolerance. Therefore, the four novel endomorphin-1 analogs can be used for preparing clinical analgesic medicines.

A kind of tetrahydro isoquinoline derivatives (I), their preparation methods, medicine compositions and medicinal uses thereof, especially their uses as κ-opioid receptor excitant in pain relieving, which belongs to the medicine chemistry. The substituents R1, R2, R3, R4 of general formula (I) are defined as the description.

The invention discloses multi-target polypeptides of opium and neuropeptide FF receptors; amino acid substitution is performed based on an opium peptide Biphalin and an NPFF chimeric peptide BN-9, and a series of multi-target polypeptides which can activate various receptors of an opium and NPFF system at the same time are obtained. By in-vitro cAMP function identification and identification of body analgesic activity and central side effects and other pharmacological activities, the multi-target polypeptides are indicated to activate the opium and NPFF receptors at the same time, have high-efficiency analgesic activity and cannot generate the analgesic tolerance phenomenon, and moreover, have the advantages of showing low side effects on body temperature, gastrointestinal motility, cardiovascular activity and the like. Therefore, the multi-target polypeptides have high application value in preparation of clinical analgesic drugs.

In consideration of physical and chemical properties that the cobratoxin is complex in component and cobratide is basic polypeptide, has molecular weight of about 7000 Dalton ad is relatively resistant to acid and alkali, and by considering the separating mechanism, the application characteristic, the long-term use stability, the cost controllability and the achievement of an extracting goal of each chromatographic column packing, the invention provides an extracting method of high-purity cobratoxin. The extracting method disclosed by the invention is stable in process, easily available in chromatography packing, low in comprehensive cost, good in operation condition adaptability and high in yield of neurotoxin. The invention further provides high-purity cobratoxin obtained by the method provided by the invention. An injection cobratide preparation prepared by the high-purity cobratoxin is less in impurities irrelevant with the treatment effect, quick to become effective in treatment effect and stable in curative effect. The invention further provides several pharmaceutical compositions taking the high-purity cobratoxin as an effective constituent formulated with preparation auxiliary materials needed for preparing a preparation as well as cobratide preparations with different dosage forms, which are suitable for being orally taken, absorbed by an oral cavity or rectal administration.

The invention relates to a method for extracting cobratide, a medicine used to treat chronic pain, the cobratide extracted by the method and a preparation containing the cobratide. The method for extracting the cobratide comprises the following steps: firstly, a stock solution of snake poison of a cobra is pretreated with ammonium sulphate to remove partial other compositions in the snake poison,is subjected to desalination and concentration through ultrafiltration, dialysis or gel chromatography, and after the concentration, is purified by a cation column, and finally is subject to freeze-drying preservation after the concentration. The cobratide preparation comprises an enteric preparation, a rectal administration preparation, a colon-specific administration preparation and so on. Withcobratide extraction and purification processes provided by the method, the purity of the extracted cobratide is more than 95 percent, and the yield reaches 70 percent; and the method is simple and reliable, and saves cost and time.

The invention discloses an integration obstetric table system with monitoring and analgesia functions which includes a base, a lifting column, a table plate and a back supporting plate, wherein the lifting column is fixed on the base and is used for supporting the table plate and one end of the back supporting plate is flexibly connected with the table plate. The table plate is divided into a front half portion and a latter half portion through a flexible connection position of the back supporting plate and the table plate. A casing body is arranged on the front half portion of the table plate. A obstetric table workstation module which is connected with an ultrasonic image module, a maternal-fetal monitoring module, a labor analgesia module, a magnetic field tracking and locating module and an obstetric table control module respectively is arranged in the casing body. Holes placing interfaces produced by connections of probes and respective modules are formed on a lateral side of the table plate. Functions of the obstetric table system have the advantages that an organic combination of every functional module is achieved, more accurate, complete and detailed obstetric characteristic parameters are acquired and measure precision and analgesia effects are improved. A structure of the obstetric table system has the advantages that cables are reduced, medical treatment space of a delivery room is saved and system applicability is improved.

Apparatus for providing transcutaneous electrical nerve stimulation (TENS) therapy to a user, the apparatus comprising: a housing; an application unit for providing mechanical coupling between the housing and the user's body; a stimulation unit for electrically stimulating at least one nerve of the user; a sensing unit for sensing the user's body movement and body orientation; and a reporting unit for providing the user with feedback based on the user's sensed body movement and body orientation.

The invention discloses application of compound traditional Chinese medicine extract in preparation of oral care health products, and relates to the technical field of oral case. Five traditional Chinese medicine extracts, namely a radix rehmanniae extract, a radix angelicae extract, a mulberry teaf extract, a gallnut extract, a white pepper extract and a pepper extract used as auxiliary medicine raw materials having an abirritation function are added into the oral care health products in a process of preparing the oral care products, so that the five traditional Chinese medicine extracts can be safely used in oral care products, such as toothpastes, mouth wash water, tooth powder, throat lozenge, chewing gum and the like, and also can have an obvious abirritation function.

The invention relates to a traditional Chinese medicine volatile oil composition for treating gastrointestinal dysfunction or irritable bowel syndrome (IBS), and a preparation method and applications thereof in the preparation of medicaments. The traditional Chinese medicine volatile oil composition is characterized by comprising the following components in parts by weight: 0-3 parts of patchouli volatile oil, 0-4 parts of atractylodes macrocephala volatile oil and 0-8 parts of orange peel volatile oil, wherein the parts of at least two components by weight are greater than 0. In the preferable scheme, the content of patchoulenone or patchouli alcohol accounts for 4-55% of the total content of the traditional Chinese medicine volatile oil composition; the content of atractylone accounts for 8-65% of the total content of the traditional Chinese medicine volatile oil composition, and the content of D-limonene accounts for 15-75% of the total content of the traditional Chinese medicine volatile oil composition. Compared with the compound crude extract, the traditional Chinese medicine volatile oil composition of the invention has a qualitative leap. The traditional Chinese medicine volatile oil composition can gather effective components, enhance the pharmacological action and the clinical curative effect, reduce the clinical dosage and be beneficial to enhancing quality control level.

The presenting invention is directed to methods and compositions for the topical or transdermal treatment of neuropathy. More particularly, transdermal or topical compositions including a combination of ingredients that provide a surprising degree of effective relief from the symptoms of peripheral neuropathy and methods for administering the compositions to treat various neuropathies.

The invention provides an anti-inflammatory, antalgic and antibacterial extract which is extracted from rape bee-pollen according to lots of process researches. Strict tests prove that the extract has anti-inflammatory, antalgic and antibacterial functions and inhibition effect on human leukocyte elastase, excellent antalgic effect on visceral pain caused by ethylic acid and external pain caused by a hot plate in mice and excellent inhibition effect on Escherichia coli, staphylococcus aureus, pseudomonas aeruginosa, bacillus subtilis and other bacterial. The extract can be used in the development of plant-source anti-inflammatory agents, antalgics and bacteriostatic agents. In addition, China's rape pollen productivity is huge, so the rape pollen can be used as the raw material for the plant-source anti-inflammatory agents, antalgics and bacteriostatic agents; and the extract has the advantages of low cost and simple process flow.

The invention relates to an external traditional Chinese medicine for treating burn, scald and various skin injuries; the medicines of raw materials of the external traditional Chinese medicine consist of rhubarb, scutellaria, phellodendron, burnet and coptis which have weight percentage of 1 to1 to1to1 to 1 to 1. The external traditional Chinese medicine belongs to a pure traditional Chinese medicine preparation, is safe, reliable and easy to obtain the medicines, has lower price, no toxic side effect, short treatment time and high curative effect and generally remains no scar after healing.

The utility model discloses an adhesive plaster for skin and a use method. The adhesive plaster comprises a fabric layer, a plaster layer and a protecting layer that are sequentially superposed and arranged, wherein the fabric layer elastically stretches along length stretching direction and is not elastic in width direction; the plaster is evenly distributed on the inside surface of the fabric layer, and the plaster takes the shape of continuous strap and is arranged at intervals along width direction; and the protecting layer is release paper or release film. In virtue of the sticky elastic property of the plaster layer and the mechanical direction of the fabric layer and in combination with the principles of kinesiology and biomechanics to influence the trend of skin and increase the gap between skin and muscle, the adhesive plaster further promotes the lymph and blood circulation, removes a number of fatigue metabolic substances in vivo, pain products, metabolic substances remaining after inflammatory reaction, small inner haemorrhage and the like, and achieves the purposes of relieving pain, slowing down inflammation, speeding up recovery and avoiding harm. The treatment process is suitable for all parts on the body surface, and widely applicable to various groups of people.